(NASDAQ: JAZZ) Jazz Pharmaceuticals's forecast annual revenue growth rate of 7.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.35%.
Jazz Pharmaceuticals's revenue in 2026 is $4,267,586,000.On average, 21 Wall Street analysts forecast JAZZ's revenue for 2026 to be $279,053,066,550, with the lowest JAZZ revenue forecast at $262,739,573,800, and the highest JAZZ revenue forecast at $291,980,740,050. On average, 21 Wall Street analysts forecast JAZZ's revenue for 2027 to be $300,476,068,350, with the lowest JAZZ revenue forecast at $272,958,591,900, and the highest JAZZ revenue forecast at $329,901,915,650.
In 2028, JAZZ is forecast to generate $325,715,811,850 in revenue, with the lowest revenue forecast at $277,390,937,100 and the highest revenue forecast at $365,914,720,400.